KOSDAQBiotech & Pharma226400

Osteonic

₩3,530▼ 1.12%2026-11-18 close
Market Cap
₩73.3B
Turnover
₩300M
Volume
80K
Shares out.
20.8M
PER
8.4×
PBR
1.0×
EPS
₩426
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Export growth, uneven quarterly profit

Export supply expansion lifted Osteonic's operating profit to the highest of the last five quarters in Q3 2026, but net profit attributable to controlling shareholders has fallen for three straight quarters, making earnings volatility the key issue.

  1. 1

    On a disclosed basis, revenue, operating profit and net profit attributable to controlling shareholders rose for three consecutive years from 2023 to 2025.

  2. 2

    Exports rose 729% in Q1 2026, and the company attributes this to expanded ODM supply to Zimmer Biomet in the United States.

  3. 3

    Q3 2026 operating profit of KRW 2.7 billion was the highest of the last five quarters, while net profit attributable to controlling shareholders fell to KRW 335 million, down 83.1% year on year.

  4. 4

    SK Securities said in an early November 2026 analysis that it maintained a Buy rating and lowered its target price to KRW 7,000.

  5. 5

    SK Securities' 2027 estimates include an operating loss of about KRW 4 billion from consolidating a newly acquired subsidiary, so the timing and size of that consolidation are the next points to check.

02

Business structure

Osteonic is a maker of orthopedic implants and medical devices. A 2022 technical analysis report described the company as a specialist manufacturer that commercializes metal and biomaterial orthopedic implants.

Its product lines are divided into craniomaxillofacial (CMF) and trauma and upper/lower extremity areas, built on metal, ceramic and ceramic-polymer composite material technology. The company is classified under biopharma, but its operations are closer to medical device manufacturing and distribution.

Sports medicine has been the main growth driver recently. According to company disclosures reported in the press, Q1 2026 sports medicine revenue was KRW 56 million-scale segment revenue of KRW 5.6 billion, more than doubling year on year, with domestic sales up 18% and exports up 729%.

The company attributes the export surge to expanded ODM supply of US-bound products to Zimmer Biomet. A securities firm noted that FDA approvals for the main product lines were completed from 2024, which laid the regulatory base for US sales.

As supply to US customers grew, overseas revenue became more dependent on a small number of customer relationships, which is the central structural feature of the business. On the customer side, the company's relationship with a global orthopedic device maker under an ODM arrangement is the defining link.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩11.9B₩2.2B18.7%
2025Q4₩13B₩2.4B18.4%
2026Q1₩12.9B₩2.3B18.1%
2026Q2₩13.2B₩2.4B18.4%
2026Q3₩13.7B₩2.7B19.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩19.8B₩2.5B₩800M12.7%2.3%68.6%
2023₩27.8B₩4.8B₩3.7B17.4%7.1%38.3%
2024₩34.2B₩6.9B₩5.6B20.1%9.5%51.6%
2025₩45.4B₩8.9B₩7.5B19.5%11.1%48.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 19.8 billion in 2022 to KRW 27.8 billion in 2023, KRW 34.2 billion in 2024 and KRW 45.4 billion in 2025, increasing for three consecutive years from 2023 to 2025. Revenue in 2025 grew 32.6% year on year and was the largest year in the 2022 to 2025 window.

Operating profit went from KRW 2.53 billion in 2022 to KRW 4.84 billion in 2023, KRW 6.89 billion in 2024 and KRW 8.86 billion in 2025, also rising for three consecutive years.

The operating margin climbed from 12.7% in 2022 to 17.4% in 2023 and 20.1% in 2024, then eased slightly to 19.5% in 2025, staying near the 20% level despite revenue growth.

Net profit attributable to controlling shareholders rose from KRW 836 million in 2022 to KRW 3.66 billion in 2023 (up 337.8%), KRW 5.65 billion in 2024 and KRW 7.5 billion in 2025. The 2023 jump was especially large, marking the year profitability recovered in earnest.

Net profit including non-controlling interests was KRW 836 million in 2022, KRW 5.65 billion in 2024 and KRW 7.5 billion in 2025, and should be read separately from the controlling-shareholder figure.

Operating cash flow went from KRW 3.99 billion in 2022 to KRW 4.14 billion in 2023, KRW 4.72 billion in 2024 and KRW 9.02 billion in 2025, with the largest increase in 2025.

At the end of 2025, total equity was KRW 67.6 billion, of which KRW 67.5 billion belonged to controlling shareholders, and total liabilities were KRW 32.9 billion. The debt-to-equity ratio fell from 68.6% in 2022 to 38.3% in 2023 and was 48.6% in 2025.

Quarterly revenue rose from KRW 11.9 billion in Q3 2025 to KRW 13 billion in Q4 2025, dipped 0.8% to KRW 12.9 billion in Q1 2026, then increased to KRW 13.2 billion in Q2 and KRW 13.7 billion in Q3 2026, with two straight quarters of growth.

Q3 2026 operating profit of KRW 2.7 billion was the highest of the last five quarters and up 21.1% year on year. Net profit attributable to controlling shareholders, however, peaked at KRW 3.74 billion in Q4 2025 and then fell to KRW 2.66 billion, KRW 1.82 billion and KRW 335 million over the next three quarters.

The gap between rising operating profit and falling controlling-shareholder profit should be traced through the non-operating items in the quarterly reports.

05

Industry analysis

In the orthopedic implant market where Osteonic operates, the company's recent export growth relies on ODM supply to global orthopedic device makers. On the demand side, press coverage cited growth in the US sports medicine market as a backdrop to Q1 2026 results.

The increase in US exports to Zimmer Biomet that began in May 2025 was the starting point for the expanded export volumes in 2026. Sangsang Securities viewed rising implant demand as a driver of the company's growth.

In cycle terms, the expansion of supply volumes looks like an early phase of acceleration, but reliance on a single US supply partner is high at this stage.

On regulation, a 2022 report noted that the company held multiple approvals including CE, FDA and Brazil's ANVISA, and completion of FDA approvals for its main product lines from 2024 laid the base for overseas sales expansion.

Domestic revenue also grew 18% in Q1 2026, indicating that the domestic base expanded alongside exports. Among peers in the same biopharma sector, many companies are built on pharmaceuticals or biologics business models, so direct comparison with sector averages is difficult. The company's position is therefore best read through its supply relationships with large global device makers.

06

Outlook

SK Securities, in an analysis published in early November 2026, estimated Q3 2026 revenue of KRW 13.7 billion and operating profit of KRW 2.8 billion, close to the disclosed Q3 operating profit of KRW 2.7 billion. The rationale was that Zimmer Biomet volumes shifted from Q2 into Q3 would restore profitability.

The same firm forecast annual operating profit of KRW 10.7 billion for 2026 and KRW 13.1 billion for 2027. Its 2027 forecast includes an operating loss of about KRW 4 billion from consolidating a newly acquired subsidiary.

SK Securities said in early November 2026 that it maintained a Buy rating and lowered its target price to KRW 7,000. These are third-party estimates and should be read separately from any company-issued figures. The next point to check is whether US export volumes for Zimmer Biomet continue after Q4 2026.

The timing of the Foxeye consolidation and the size of the acquired unit's losses will also determine whether 2027 results match the estimate.

07

Valuation

PER
8.4×
PBR
1.0×
ROE
12.6%
EPS
₩426
BPS
₩3,604
Dividend per share
₩0

The price-to-book ratio was roughly between 1.4x and 2.2x at year-end levels from 2022 to 2024. The current multiple of net assets sits toward the lower end of that past year-end range. Comparing against this historical range is one framework for explaining the gap.

Earnings-based multiples vary widely depending on the period used. Using the 2025 annual net profit attributable to controlling shareholders of KRW 7.5 billion and the last four quarters total of KRW 8.55 billion yields different results because the periods differ.

Since controlling-shareholder profit has declined for three straight quarters, earnings-based multiples should be read together with the quarterly trend. Cash returns through dividends are low, so shareholder yield depends mainly on the profit growth path.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Expanding US export supply

Exports rose 729% in Q1 2026, and the company attributes this to expanded ODM supply to Zimmer Biomet in the United States. US-bound supply that began in May 2025 has grown in volume during 2026. Sports medicine segment revenue reached KRW 5.6 billion in Q1 2026, more than doubling year on year.

Operating profit trend and margin level

Operating profit rose for three consecutive years, from KRW 2.53 billion in 2022 to KRW 8.86 billion in 2025. The operating margin stayed near 20% at 20.1% in 2024 and 19.5% in 2025. Q3 2026 operating profit of KRW 2.7 billion was the highest of the last five quarters.

Low financial burden

Total equity at the end of 2025 was KRW 67.6 billion and total liabilities were KRW 32.9 billion. The debt-to-equity ratio fell from 68.6% in 2022 to 38.3% in 2023 before reaching 48.6% in 2025. Operating cash flow in 2025 was KRW 9.02 billion, up sharply from the prior year.

09

Bear factors

Consecutive declines in controlling-shareholder profit

Net profit attributable to controlling shareholders peaked at KRW 3.74 billion in Q4 2025 and then fell to KRW 2.66 billion, KRW 1.82 billion and KRW 335 million over the next three quarters. Q3 2026 was down 83.1% year on year. The gap between rising operating profit and falling net profit still needs explanation.

Customer concentration in exports

Export growth centers on ODM supply to Zimmer Biomet in the United States. As exports rose 729%, the influence of one customer's order size on revenue has grown. A change in that customer's order timing or volume could move quarterly revenue and operating profit together.

Acquisition losses and a lower target price

SK Securities reflected an operating loss of about KRW 4 billion from consolidating a newly acquired subsidiary in its 2027 estimates. SK Securities said in early November 2026 that it lowered its target price to KRW 7,000. How the acquired unit's results will flow into reported earnings remains to be confirmed.

10

Risk factors

Customer concentration risk

Export expansion relies heavily on ODM supply to Zimmer Biomet in the United States. Changes in that customer's orders or supply terms feed directly into export revenue. Although domestic revenue grew 18%, the larger share of overseas volume has also raised quarterly earnings volatility.

Quarterly earnings volatility

Q3 2026 operating profit was KRW 2.7 billion, while net profit attributable to controlling shareholders was only KRW 335 million. The widening gap between the two measures calls for a check on earnings quality.

Annual profit improved through 2025, but on a quarterly basis net profit has declined for three consecutive quarters.

Post-acquisition earnings impact

A securities firm's 2027 estimate reflects the consolidation of a newly acquired subsidiary, which carries an operating loss of about KRW 4 billion. Core operating improvement could be offset by this loss.

Until the consolidation timing and the acquired unit's earnings structure are clearer, the estimate carries uncertainty.

11

What to watch next

  1. Early February 2027 (estimated from last year's provisional disclosure timing)

    Q4 and full-year 2026 provisional results. This is the point to see whether the three-quarter decline in controlling-shareholder profit reverses in Q4 and whether Zimmer Biomet export volumes continue into year-end.

  2. Late March 2027

    Filing deadline for the 2026 annual business report. It provides the detail on operating margin, debt-to-equity ratio, operating cash flow and non-operating items.

  3. Mid-May 2027 (estimated from the Q1 2026 disclosure timing)

    Q1 2027 results. This shows how much of the 729% export growth seen in Q1 2026 has been sustained, and how actual results compare with securities-firm estimates.

  4. During 2027 (consolidation timing not yet set)

    The timing of the Foxeye consolidation and the size of the operating loss recorded after it. This tests whether the roughly KRW 4 billion loss in securities-firm estimates shows up in reported results.

12

Overall view

Osteonic's revenue, operating profit and net profit attributable to controlling shareholders rose for three consecutive years from 2023 to 2025. Export growth from ODM supply to Zimmer Biomet in the United States is the main growth driver, and exports rose 729% in Q1 2026.

Revenue and operating profit grew for two straight quarters in 2026, but net profit attributable to controlling shareholders fell for three straight quarters, increasing earnings volatility. The last four quarters' total for that net profit is KRW 8.55 billion.

On the financial side, the debt-to-equity ratio of 48.6% and total equity of KRW 67.6 billion at the end of 2025 indicate a relatively light burden.

Securities-firm estimates put 2026 operating profit at KRW 10.7 billion and 2027 at KRW 13.1 billion, with the 2027 figure including a loss from consolidating a newly acquired subsidiary. Strengths and weaknesses coexist, and export concentration and quarterly earnings swings are the key variables.

The next checkpoints are the early February 2027 provisional results, the late March 2027 annual report, and the timing of the Foxeye consolidation.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. investing.com
  2. thevc.kr
  3. ssl.pstatic.net
  4. stockanalysis.com
  5. tipranks.com
  6. sks.co.kr
  7. file.alphasquare.co.kr
  8. moneyrecipe.blog
  9. economytalk.kr
  10. dailypharm.com
  11. edaily.co.kr
  12. comp.fnguide.com
  13. vegannews.co.kr
  14. edaily.co.kr
  15. pharm.edaily.co.kr
  16. view.asiae.co.kr
  17. newspim.com
  18. businesspost.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis